BBLG
Bone BiologicsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-22
Current thesis
The constructive case is that BBLG still has a defined clinical-regulatory path for NB1: the Australia pilot is underway, the study design is set at up to 30 subjects, and management frames that work as a bridge toward a later U.S. IDE and PMA path [#10-K-2026-03-02].
Posture
Constructive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.2.
What can break
Clinical enrollment slippage or weak data from the Australia NB1 pilot
Momentum
82
Value
57
Sentiment
35
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $0.90 · Bull $2.20 · Bear $0.35
Data freshness
Prices
As of 2026-07-22
Fundamentals
As of 2026-07-22 • Vendor: Data Vendor v1
Scores
As of 2026-07-22 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-22
Investment thesis
As of 2026-07-22
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $12.20
Why
Momentum82 · Δ7d -
Value57 · Δ7d -0.2
Sentiment35 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Value · See fundamentals
Momentum
82
26% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
57
39% active weight
Current posture
7d trendFlat
Δ7d
-0.2
Δ21d
-0.4
Sentiment
35
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade B. Momentum 81.9 / Value 57.5 / Sentiment 34.7
Fundamentals (TTM)As of 2026-07-22
Fundamentals (TTM)
As of 2026-07-22
Market Cap
$1.99M
Beta
0.75
Shares Out
1.81M
P/E (TTM) · Derived
-0.4
P/S (TTM)
-
P/FCF (TTM) · Derived
-0.55
Rev YoY
-
EPS YoY
-77.7%
Gross Margin
-
Op Margin
-
Net Debt
-$5.33M
Current Ratio
16.09
As of 2026-07-22 • Updated nightlySource: Internal modelMethodology